Positive Results for MaaT033 Clinical Trial

MaaT Pharma, a biotechnology company based in Lyon, announced positive results from its Phase 2b clinical trial evaluating MaaT033. The independent DSMB committee recommended the continuation of the trial without modification after a safety assessment. MaaT033, an oral drug developed from multiple donors, showed a consistent safety profile. The PHOEBUS trial, the largest of its kind in oncology, aims to include 387 patients and spans several European countries.

With 80 patients enrolled by the end of 2024, the study is continuing at a good pace in 54 clinical centers. Upcoming milestones include regular DSMB assessments, including mortality, scheduled for 2025. Previous data had already confirmed the good safety profile of MaaT033, particularly in patients with acute myeloid leukemia.